Impact of Pharmacy Benefit Design on Prescription Drug Utilization: a Fixed Effects Analysis of Plan Sponsor Data

Overview

Journal Health Serv Res

Specialty Health Services

Date 2009 Feb 4

PMID 19187183

Citations 8

Authors

M Christopher Roebuck

Joshua N Liberman

Affiliations

Soon will be listed here.

Abstract

Objective: To study the impact of various elements of pharmacy benefit design on both the absolute and relative utilization of generics, brands, retail pharmacy, and mail service.

Data Source: Panel data on 1,074 plan sponsors covering 21.6 million individuals over 12 calendar quarters (2005-2007).

Study Design: A retrospective analysis of pharmacy claims.

Statistical Methods: To control for potential endogeneity, linear fixed effects models were estimated for each of six dependent variables: the generic utilization rate, the brand utilization rate, the generic dispensing rate (GDR), the retail pharmacy utilization rate, the mail service utilization rate, and the mail distribution rate.

Principal Findings: Most member cost-share variables were nonlinearly associated with changes in prescription drug utilization. Marginal effects were generally greater in magnitude for brand out-of-pocket costs than for generic out-of-pocket costs. Time dummies, as well as other pharmacy benefit design elements, also yielded significant results.

Conclusions: Prior estimates of the effect of member cost sharing on prescription drug utilization may be biased if complex benefit designs, mail service fulfillment, and unmeasured factors such as pharmaceutical pipelines are not accounted for. Commonly cited relative utilization metrics, such as GDR, may be misleading if not examined alongside absolute prescription drug utilization.

Citing Articles

Sheer R, Schwab P, Noyes Essex M, Cappelleri J, Reiners A, Bobula J Drugs Aging. 2018; 35(10):937-950.

PMID: 30203313 DOI: 10.1007/s40266-018-0585-8.

Influencers of generic drug utilization: A systematic review.

Howard J, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R Res Social Adm Pharm. 2017; 14(7):619-627.

PMID: 28814375 PMC: 5910277. DOI: 10.1016/j.sapharm.2017.08.001.

Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.

Li P, Schwartz J, Doshi J J Am Heart Assoc. 2016; 5(11).

PMID: 27836822 PMC: 5210334. DOI: 10.1161/JAHA.116.003377.

Estimating the Effect of Health Insurance on Personal Prescription Drug Importation.

Zullo A, Howe C, Galarraga O Med Care Res Rev. 2016; 74(2):178-207.

PMID: 26837427 PMC: 4970983. DOI: 10.1177/1077558716629039.

A comparison of drug formularies and the potential for cost-savings.

Kjos A, Schommer J, Yuan Y Am Health Drug Benefits. 2014; 3(5):321-30.

PMID: 25126325 PMC: 4106615.

References

Gilman B, Kautter J . Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries. Health Serv Res. 2008; 43(2):478-95. PMC: 2442369. DOI: 10.1111/j.1475-6773.2007.00774.x. View

Motheral B, Fairman K . Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001; 39(12):1293-304. DOI: 10.1097/00005650-200112000-00005. View

Landsman P, Yu W, Liu X, Teutsch S, Berger M . Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005; 11(10):621-8. View

Huskamp H, Deverka P, Landrum M, Epstein R, McGuigan K . The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees. Health Serv Res. 2007; 42(5):1926-42. PMC: 2254563. DOI: 10.1111/j.1475-6773.2007.00722.x. View

Ellis R, Manning W . Optimal health insurance for prevention and treatment. J Health Econ. 2007; 26(6):1128-50. DOI: 10.1016/j.jhealeco.2007.09.002. View

Fairman K, Motheral B, Henderson R . Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2004; 25(12):3147-61. DOI: 10.1016/s0149-2918(03)90099-3. View

Newhouse J . Reconsidering the moral hazard-risk avoidance tradeoff. J Health Econ. 2006; 25(5):1005-14. DOI: 10.1016/j.jhealeco.2006.06.003. View

Daniel Mullins C, Palumbo F, Saba M . Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index. Am J Manag Care. 2007; 13(6 Pt 2):377-84. View

Nair K, Wolfe P, Valuck R, McCollum M, Ganther J, Lewis S . Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003; 9(2):123-33. PMC: 10437185. DOI: 10.18553/jmcp.2003.9.2.123. View

10.

Brixner D, Joish V, Odera G, Avey S, Hanson D, Cannon H . Effects of benefit design change across 5 disease states. Am J Manag Care. 2007; 13(6 Pt 2):370-6. View

11.

Leibowitz A, Manning W, NEWHOUSE J . The demand for prescription drugs as a function of cost-sharing. Soc Sci Med. 1985; 21(10):1063-9. DOI: 10.1016/0277-9536(85)90161-3. View

12.

Mager D, Cox E . Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate. Am J Manag Care. 2007; 13(6 Pt 2):347-52. View

13.

Rector T, Finch M, Danzon P, Pauly M, Manda B . Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003; 41(3):398-406. DOI: 10.1097/01.MLR.0000053022.47132.82. View

14.

Huskamp H, Deverka P, Epstein A, Epstein R, McGuigan K, Frank R . The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003; 349(23):2224-32. DOI: 10.1056/NEJMsa030954. View

15.

Shrank W, Young H, Ettner S, Glassman P, Asch S, Kravitz R . Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care. 2005; 11(1):16-22. View

16.

Goldman D, Joyce G, Escarce J, Pace J, Solomon M, Laouri M . Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004; 291(19):2344-50. DOI: 10.1001/jama.291.19.2344. View

17.

Landon B, Rosenthal M, Normand S, Spettell C, Lessler A, Underwood H . Incentive formularies and changes in prescription drug spending. Am J Manag Care. 2007; 13(6 Pt 2):360-9. View

18.

Manning W, NEWHOUSE J, Duan N, Keeler E, Leibowitz A, Marquis M . Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987; 77(3):251-77. View

19.

Chernew M, Shah M, Wegh A, Rosenberg S, Juster I, Rosen A . Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008; 27(1):103-12. DOI: 10.1377/hlthaff.27.1.103. View

20.

Gemmill M, Costa-Font J, McGuire A . In search of a corrected prescription drug elasticity estimate: a meta-regression approach. Health Econ. 2007; 16(6):627-43. DOI: 10.1002/hec.1190. View